tert-butyl 7-hydroxy-4-oxospiro[chroman-2,4'-piperidine]-1'-carboxylate | 956605-22-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并吡喃
• 英文名称: tert-butyl 7-hydroxy-4-oxospiro[chroman-2,4'-piperidine]-1'-carboxylate
• 英文别名: tert-butyl 7-hydroxy-4-oxospiro[3H-chromene-2,4'-piperidine]-1'-carboxylate
• CAS: 956605-22-4
• 化学式: C₁₈H₂₃NO₅
• 分子量: 333.384
• InChiKey: HUFKEQOIGLJLSW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  24
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.56
• 拓扑面积：
  76.1
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  tert-butyl 7-hydroxy-4-oxospiro[chroman-2,4'-piperidine]-1'-carboxylate 在 potassium carbonate 、 lithium bromide 作用下， 以 甲醇 、 丙酮 为溶剂， 反应 24.0h， 生成 Tert-butyl 7-(3-anilino-2-hydroxy-propoxy)-4-oxo-spiro[chromane-2,4'-piperidine]-1'-carboxylate
  参考文献：
  名称：

  Synthesis and antitubercular activity of amino alcohol fused spirochromone conjugates

  摘要：

  A series of 21 new amino alcohol fused spirochromone conjugates have been synthesized, characterized with analytical data and evaluated their antimycobacterial activity against Mycobacterium tuberculosis (virulent strain H37Rv) in vitro. Some of the compounds exerted significant inhibition, in particular, compound 4f found to be the most potent derivative exhibiting MIC = 3.13 mu g/mL. (C) 2013 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2012.12.073
• 作为产物：
  描述：

  2,4-二羟基苯乙酮 、 1-Boc-2-哌啶酮 以 乙腈 为溶剂， 反应 12.0h， 以75%的产率得到tert-butyl 7-hydroxy-4-oxospiro[chroman-2,4'-piperidine]-1'-carboxylate
  参考文献：
  名称：

  Synthesis and antitubercular activity of amino alcohol fused spirochromone conjugates

  摘要：

  A series of 21 new amino alcohol fused spirochromone conjugates have been synthesized, characterized with analytical data and evaluated their antimycobacterial activity against Mycobacterium tuberculosis (virulent strain H37Rv) in vitro. Some of the compounds exerted significant inhibition, in particular, compound 4f found to be the most potent derivative exhibiting MIC = 3.13 mu g/mL. (C) 2013 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2012.12.073

文献信息

• HETEROCYCLIC COMPOUND
  申请人：Takeda Pharmaceutical Company Limited

  公开号：EP2123652A1

  公开（公告）日：2009-11-25

  The present invention provides a compound having an ACC inhibitory action, which is useful for the prophylaxis or treatment of obesity, diabetes, hypertension, hyperlipidemia, cardiac failure, diabetic complications, metabolic syndrome, sarcopenia, cancer and the like, and has superior efficacy. The present invention provides a compound represented by the formula (I): wherein each symbol is as in the specification, or a salt thereof.

  本发明提供了一种具有ACC抑制作用的化合物，该化合物用于预防或治疗肥胖、糖尿病、高血压、高脂血症、心力衰竭、糖尿病并发症、代谢综合征、肌肉减少症、癌症等疾病，并具有优异的疗效。 本发明提供了一种由公式（I）表示的化合物： 其中每个符号如说明书所述，或其盐。
• Spirocyclic sulfonamides with carbonic anhydrase inhibitory and anti-neuropathic pain activity
  作者：Y. Kalisha Vali、Rambabu Gundla、Om V. Singh、Yasinalli Tamboli、Lorenzo Di Cesare Manelli、Carla Ghelardini、Abdul-Malek S. Al-Tamimi、Fabrizio Carta、Andrea Angeli、Claudiu T. Supuran

  DOI：10.1016/j.bioorg.2019.103210

  日期：2019.11

  A novel series of 4-oxo-spirochromane bearing primary sulfonamide group were synthetized as Carbonic Anhydrase inhibitors (CAIs) and tested for their management of neuropathic pain. Indeed, CAs have been recently validated as novel therapeutic targets in neuropathic pain. All compounds, here reported, showed strong activity against hCA II and hCA VII with KI values in the low or sub-nanomolar range

  合成一系列新型的带有4-氨基氧代螺氨基甲烷的伯磺酰胺基团作为碳酸酐酶抑制剂（CAIs），并测试其对神经性疼痛的治疗作用。实际上，最近已经证实CA是神经性疼痛中的新型治疗靶标。本文报道的所有化合物均显示出针对hCA II和hCA VII的强活性，其K I值处于低或亚纳摩尔范围内。在奥沙利铂诱发的神经病动物模型中，两种化合物（6d和6l）显示出良好的神经痛减轻作用，且持续时间长于药物参考乙酰唑胺。
• Spirocyclic Heterocyclic Derivatives And Methods Of Their Use
  申请人：Dolle E. Roland

  公开号：US20080102031A1

  公开（公告）日：2008-05-01

  Spirocyclic heterocyclic derivatives, pharmaceutical compositions containing these compounds, and methods for their pharmaceutical use are disclosed. In certain embodiments, the spirocyclic heterocyclic derivatives are ligands of the δ opioid receptor and may be useful, inter alia, for treating and/or preventing pain, anxiety, gastrointestinal disorders, and other δ opioid receptor-mediated conditions.

  本发明公开了螺环异杂环衍生物、含有这些化合物的制药组合物以及它们的制药用途方法。在某些实施例中，螺环异杂环衍生物是δ阿片受体的配体，可能有助于治疗和/或预防疼痛、焦虑、胃肠疾病和其他δ阿片受体介导的疾病等。
• SPIROCYCLIC HETEROCYCLIC DERIVATIVES AND METHODS OF THEIR USE
  申请人：Dolle Roland E.

  公开号：US20100029614A1

  公开（公告）日：2010-02-04

  Spirocyclic heterocyclic derivatives, pharmaceutical compositions containing these compounds, and methods for their pharmaceutical use are disclosed. In certain embodiments, the spirocyclic heterocyclic derivatives are ligands of the δ opioid receptor and may be useful, inter alia, for treating and/or preventing pain, anxiety, gastrointestinal disorders, and other δ opioid receptor-mediated conditions.

  本发明公开了螺环杂环衍生物、含有这些化合物的制药组合物以及它们的制药用途的方法。在某些实施例中，螺环杂环衍生物是δ阿片受体的配体，并且可能有用于治疗和/或预防疼痛、焦虑、胃肠障碍和其他δ阿片受体介导的疾病等方面。
• METHODS FOR ENHANCING COGNITIVE FUNCTION
  申请人：Dolle E. Roland

  公开号：US20080119452A1

  公开（公告）日：2008-05-22

  Methods for enhancing cognitive function are disclosed. More particularly, methods are disclosed for enhancing cognitive function comprising the step of administering spirocyclic heterocyclic derivatives (including derivatives of spiro(2H-1-benzopyran-2,4′-piperidines) of the general formula IV:

  本发明揭示了增强认知功能的方法。更具体地，本发明揭示了一种增强认知功能的方法，其中包括给予螺环杂环衍生物（包括公式IV的螺(2H-1-苯并吡喃-2,4'-哌啶)衍生物）的步骤。